Twain Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$5.96M
- Investors
-
2
Twain Therapeutics General Information
Description
Developer of cancer immunotherapy treatment designed for antibody-based IL-2 receptor agonists. The company is developing an antibody that interacts with receptors which promotes a cytotoxic T cell-mediated anti-tumor response with the least side effects, enabling the healthcare industry to offer patients safe and effective therapeutics that address treatment challenges.
Contact Information
Website
www.twaintherapeutics.comCorporate Office
- Block 531, Upper Cross Street
- Hong Lim Complex, Number 03-62
- Singapore, 050531
- Singapore
Corporate Office
- Block 531, Upper Cross Street
- Hong Lim Complex, Number 03-62
- Singapore, 050531
- Singapore
Twain Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 01-Jun-2022 | $5.96M | Completed | Startup |
Twain Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Twain Therapeutics Patents
Twain Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026033132-A1 | Antigen-binding molecules | Pending | 09-Aug-2024 | ||
| WO-2026033134-A1 | Antigen-binding molecules | Pending | 09-Aug-2024 | ||
| WO-2026033139-A1 | Antigen-binding molecules | Pending | 09-Aug-2024 | ||
| EP-4646225-A1 | Antigen-binding molecules | Pending | 06-Jan-2023 | ||
| EP-4646274-A1 | Antigen-binding molecules | Pending | 06-Jan-2023 | A61P37/06 |
Twain Therapeutics Signals
Twain Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Accelerate Technologies | Corporation | Minority | ||
| Parker Institute for Cancer Immunotherapy | Corporation | Minority |
Twain Therapeutics FAQs
-
When was Twain Therapeutics founded?
Twain Therapeutics was founded in 2020.
-
Where is Twain Therapeutics headquartered?
Twain Therapeutics is headquartered in Singapore, Singapore.
-
What is the size of Twain Therapeutics?
Twain Therapeutics has 6 total employees.
-
What industry is Twain Therapeutics in?
Twain Therapeutics’s primary industry is Biotechnology.
-
Is Twain Therapeutics a private or public company?
Twain Therapeutics is a Private company.
-
What is the current valuation of Twain Therapeutics?
The current valuation of Twain Therapeutics is .
-
What is Twain Therapeutics’s current revenue?
The current revenue for Twain Therapeutics is .
-
How much funding has Twain Therapeutics raised over time?
Twain Therapeutics has raised $5.96M.
-
Who are Twain Therapeutics’s investors?
Accelerate Technologies and Parker Institute for Cancer Immunotherapy have invested in Twain Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process